TELO Stock Forecast: Telomir Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.36
−17.27% on the day

The median 12-month analyst price target for Telomir Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$26.8M
Ticker Nerd rank
27/ 100
Median analyst target
$4.00
Analysts covering
1
Revenue$0.0
Operating income−$1.8M
Net income−$1.7M
Free cash flow−$1.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−25.9%
1M
−64.0%
YTD
−72.6%
1Y
−73.8%
From 52W high
−75.6%
From 52W low
0.0%
$0.36
$1.49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Telomir Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
27/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Value
47
Revisions
41
Growth
38
Volatility
34
Momentum
22
Issuance
16
Quality
12

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TELO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TELO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26TELOHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$4.00
Low
$4.00
Median
$4.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Sept 2026Maxim GroupInitiatesBuy$4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TELO.

Market Radar

This page is one stock. Monday covers all of them.

TELO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TELO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Telomir Pharmaceuticals, Inc. returned −73.8% against +6.9% for the S&P 500, dividends included.

TELO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26TELOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TELO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
5.7×

Cheaper than 15% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−96.3%

Higher than 14% of US stocks

Return on assets
−59.0%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Telomir Pharmaceuticals, Inc. has a market value of $26.8M and an enterprise value of $22.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$5.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$4.9M.

  • Shares outstanding: 68.8M.

  • Telomir Pharmaceuticals, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

TELO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TELOTelomir Pharmaceuticals, Inc.$26.8M27
KLRSKalaris Therapeutics, Inc.$26.8M27
EYPTEyePoint, Inc.$26.6M21
EXOZeXoZymes, Inc.$27.0M11
EDSAEdesa Biotech, Inc.$27.0M49
LONALeonaBio, Inc.$26.4M25
INMBINmune Bio, Inc.$25.6M38

Take a look at TELO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Telomir Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TELO

What is the TELO stock price forecast for 2026-2027?

The median 12-month analyst price target for Telomir Pharmaceuticals, Inc. is $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TELO stock a buy right now?

Of the 1 analyst covering Telomir Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Telomir Pharmaceuticals, Inc. 27 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TELO?

As at 21 Nov 2026, Telomir Pharmaceuticals, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will TELO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $4, and Ticker Nerd's factor model ranks Telomir Pharmaceuticals, Inc. 27 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TELO stock forecast for 2030?

No analyst covering Telomir Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has TELO stock performed over the past year?

Telomir Pharmaceuticals, Inc. returned -73.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Telomir Pharmaceuticals, Inc. do?

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. Its lead program centers on Telomir-1, an oral small molecule being studied for its ability to regulate metal ions and support cellular processes linked to telomere maintenance, epigenetic control, and inflammatory pathways.

Company

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. Its lead program centers on Telomir-1, an oral small molecule being studied for its ability to regulate metal ions and support cellular processes linked to telomere maintenance, epigenetic control, and inflammatory pathways. The company’s research spans a range of therapeutic areas, including oncology, metabolic disorders, ophthalmology, and neurodegenerative conditions. Telomir Pharmaceuticals, Inc. positions its platform around targeting underlying mechanisms rather than isolated symptoms, with current work aimed at advancing therapies for conditions such as triple-negative breast cancer, Wilson’s disease, type 2 diabetes, age-related macular degeneration, Alzheimer’s disease, and Progeria. The company is headquartered in Tampa, Florida.

CEO Mr. Erez Aminov · 1 employees · United States · https://telomirpharma.com